Adaptimmune Therapeutics PLC
NASDAQ:ADAP
EV/GP
Enterprise Value to Gross Profit
Market Cap | EV/GP | ||||
---|---|---|---|---|---|
UK |
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
|
316.9m USD | 0 | ||
US |
Abbvie Inc
NYSE:ABBV
|
289.2B USD | 9.1 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
171.1B USD | 11.3 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.7B USD | 11.7 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
107.8B USD | 8.8 | ||
AU |
CSL Ltd
ASX:CSL
|
136.7B AUD | 13.9 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
83.5B USD | 3.8 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
49.4B USD | 35.9 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 24.2 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
34.3B USD | 5.4 | ||
KR |
Celltrion Inc
KRX:068270
|
39.6T KRW | 38.5 |
EV/GP Forward Multiples
Forward EV/GP multiple is a version of the EV/GP ratio that uses forecasted gross profit for the EV/GP calculation. 1-Year, 2-Years, and 3-Years forwards use gross profit forecasts for 1, 2, and 3 years ahead, respectively.